Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. حسب Peiqi Yin (6533747)

Naringenin decreases total cell viability. حسب Lauren A. Eanes (20995499)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Table 5_Road transportation is associated with decreased intestinal motility in horses.docx حسب Sharanne L. Raidal (3097719)

"…Horses with high heart rates, high sweat scores or abnormal demeanour on arrival demonstrated decreased intestinal motility. Salivary cortisol concentrations increased after transportation (mean difference, 95% CI, for T0 vs T1 was 1.66, 1.09−2.53 nmol/L) and were inversely associated with intestinal motility. …"

Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive... حسب Elie Mulhem (22537863)

الموضوعات:

MiR-129-5p levels were decreased in mouse depression models. حسب Qiaozhen Qin (13159201)

الموضوعات:

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. حسب Cristina Dolciotti (16317330)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. حسب Penghui Hu (695020)

CM-DWM-EC chart using 30% decrease in the mean for the E(KeV). حسب Shumaila Nisar (20114256)

"…<p>CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).</p>…"

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات: